Human oncology programme progresses to Clinical Phase IIA
April, 2018 Update
Our human programme for tigilanol tiglate reached an exciting milestone as we plan for the Clinical Phase IIA trial. We are now actively collaborating with highly engaged key opinion leader oncologists to finalise trial strategy and protocol. In addition, the Clinical Phase I/IIA safety trial is in the final stages of report writing. Results from this trial are planned for submission to a peer reviewed global scientific journal for publication as well as presentation at global pharmaceutical industry conferences.